Poseida in the News

Explore recent media coverage of Poseida and find out how we are creating the next wave of cell and gene therapies with the capacity to cure.

Getting Closer to Single-Treatment Cures at Poseida Therapeutics

CRISPR Medicine News | September 6, 2021

Novel CAR T-Cell Therapy P-PSMA-101 Shows Promise in mCRPC

Targeted Oncology | September 1, 2021

Poseida’s CAR-T Cell Therapy for Prostate Cancer Shows Promising Durable Response in Phase 1

GeneTherapyLive | September 1, 2021

P-PSMA-101 Elicits Encouraging Responses in Metastatic Castration-Resistant Prostate Cancer

OncLive | September 1, 2021

Poseida Therapeutics: Creating the Next Wave of Cell & Gene Therapies With the Capacity to Cure

Drug Development & Delivery | September 2021

Poseida Presents Encouraging Preliminary Data for Autologous CAR-T Candidate Against Solid Tumors

GeneOnline News | August 31, 2021

FDA clears IND application for BCMA-directed allogenic CAR-T to treat multiple myeloma

Healio (Hem/Onc Today) | August 30, 2021

The Top 100 Healthcare Technology Companies of 2021

The Healthcare Technology Report | August 24, 2021

Using Gene Therapies to Fight Cancer and Tumor Cell Therapeutics – An In-Depth Discussion with Eric Ostertag

Finding Genius Podcast | June 25, 2021

‘One-and-Done’ Gene Therapies: A Near-Term Niche?

KPMG US Video Interview | June 24, 2021

GMP CAR T Manufacturing: The Poseida Approach

BioProcess Online | June 7, 2021

Women of Influence

PharmaVoice | April 2021

Will blood cancer medical advances begin with BCMA?

Nature BioPharma Dealmakers | March 1, 2021

Moving Beyond Viral Vectors for Gene Therapies

RARECast podcast interview | February 19, 2021

#TradeTalks​: The ultimate promise of cell and gene therapy

Nasdaq TradeTalks interview | February 17, 2021

Scrip Asks…What Does 2021 Hold For Biopharma? Part 4: Technology And Disease

Scrip | February 9, 2021

Commanders & Chiefs: Biopharma Chief Executive Officers

PharmaVoice | January 2021